Anti-CD11a Antibody, Highly Galactosylated (CAT#: BioBet-GA-056ZP) Datasheet

CD11A

CD11A

ITGAL encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed on all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity.

CD11A; LFA-1; ITGAL

Plasma membrane

Its related pathways are Integrin Pathway and Degradation of the extracellular matrix.

Integrin ITGAL/ITGB2 is the receptor for ICAM1, ICAM2, ICAM3 and ICAM4. The integrin ITGAL/ITGB2 is the receptor for F11R (PubMed:11812992, PubMed:15528364). Integin ITGAL/ITGB2 is the receptor for the secreted ubiquitin-like protein ISG15; this interaction is mediated by ITGAL (PubMed: 29100055). Participate in a variety of immune phenomena, including leukocyte-endothelial cell interaction, cytotoxic T cell-mediated killing, and antibody-dependent killing of granulocytes and monocytes. Contribute to natural killer cell toxicity (PubMed: 15356110). Participate in the adhesion and transport of leukocytes including T cells and neutrophils (PubMed:11812992). There is a need to generate common lymphoid progenitor cells in the bone marrow, demonstrating its role in lymphogenesis (through similarity). The integrin ITGAL/ITGB2 is related to ICAM3 and contributes to the phagocytosis of macrophages and neutrophils (PubMed:23775590).

In resting T-cells, up to 40% of surface ITGAL is constitutively phosphorylated. Phosphorylation causes conformational changes needed for ligand binding and is necessary for activation by some physiological agents.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

BioBet-GA-056ZP

Human

Human

Efalizumab, sold under the trade name Raptiva, is a drug previously used to treat autoimmune diseases. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1, and was originally used to treat psoriasis. .

Moderate to Severe Chronic Plaque Psoriasis

For the treatment of adult patients with moderate to severe chronic plaque psoriasis, these patients are suitable for phototherapy or systemic therapy.